What is the dosage of Actemra?

Actemra is available in 5 dosages, including 180 mg/ml Auto-Injector 0.9 ml, 180 mg/ml Prefilled Syringe 0.9 ml, 20 mg/ml Injection 10 ml, 20 mg/ml Injection 20 ml and 20 mg/ml Injection 4 ml

What does Actemra treat?

Actemra treats Juvenile Arthritis, Rheumatoid Arthritis and Giant Cell Arteritis

What is Actemra made of?

Actemra contains tocilizumab which is a Interleukin-6 Receptor Antagonist

How is Actemra administered?

Actemra is administered as a Injectable

What is Actemra mechanism of action?

Actemra mechanism of action is Interleukin 6 Receptor Antagonists

Actemra

(tocilizumab)

0.9 ML tocilizumab 180 MG/ML Auto-Injector [Actemra]0.9 ML tocilizumab 180 MG/ML Prefilled Syringe [Actemra]

View 3 more

BLACK BOX WARNING

Dosage & administration

For RA, pJIA and sJIA, ACTEMRA may be used alone or in combination with methotrexate: and in RA, other DMARDs may be used.

General Administration and Dosing Information

* RA, GCA, SSc-ILD, PJIA and SJIA – It is recommended that ACTEMRA not be initiated in patients with an absolute neutrophil count (ANC) below 2000 per mm3, platelet count below 100,000 per mm3, or ALT or AST above 1.5 times the upper limit of normal (ULN).
* COVID-19 – It is recommended that ACTEMRA not be initiated in patients with an absolute neutrophil count (ANC) below 1000 per mm3, platelet count below 50,000 mm3, or ALT or AST above 10 times ULN .
* In RA, CRS or COVID-19 patients, ACTEMRA doses exceeding 800 mg per infusion are not recommended.
* In GCA patients, ACTEMRA doses exceeding 600 mg per infusion are not recommended.

Rheumatoid Arthritis

Recommended Adult Intravenous Dosage:

When used in combination with DMARDs or as monotherapy the recommended starting dose is 4 mg per kg every 4 weeks followed by an increase to 8 mg per kg every 4 weeks based on clinical response.

Recommended Adult Subcutaneous Dosage:

Patients less than 100 kg weight	162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response
Patients at or above 100 kg weight	162 mg administered subcutaneously every week

Giant Cell Arteritis

Recommended Adult Intravenous Dosage:

The recommended dose is 6 mg per kg every 4 weeks in combination with a tapering course of glucocorticoids. ACTEMRA can be used alone following discontinuation of glucocorticoids.

Recommended Adult Subcutaneous Dosage:

The recommended dose is 162 mg given once every week as a subcutaneous injection, in combination with a tapering course of glucocorticoids.

A dose of 162 mg given once every other week as a subcutaneous injection, in combination with a tapering course of glucocorticoids, may be prescribed based on clinical considerations.

ACTEMRA can be used alone following discontinuation of glucocorticoids.

Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Recommended Adult Subcutaneous Dosage:

The recommended dose of ACTEMRA for adult patients with SSc-ILD is 162 mg given once every week as a subcutaneous injection.

Polyarticular Juvenile Idiopathic Arthritis

Recommended Intravenous PJIA Dosage Every 4 Weeks
Patients less than 30 kg weight	10 mg per kg
Patients at or above 30 kg weight	8 mg per kg

Recommended Subcutaneous PJIA Dosage
Patients less than 30 kg weight	162 mg once every three weeks
Patients at or above 30 kg weight	162 mg once every two weeks

Systemic Juvenile Idiopathic Arthritis

Recommended Intravenous SJIA Dosage Every 2 Weeks
Patients less than 30 kg weight	12 mg per kg
Patients at or above 30 kg weight	8 mg per kg

Recommended Subcutaneous SJIA Dosage
Patients less than 30 kg weight	162 mg every two weeks
Patients at or above 30 kg weight	162 mg every week

Cytokine Release Syndrome

Recommended Intravenous CRS Dosage
Patients less than 30 kg weight	12 mg per kg
Patients at or above 30 kg weight	8 mg per kg
Alone or in combination with corticosteroids.

Coronavirus Disease 2019

The recommended dosage of ACTEMRA for adult patients with COVID-19 is 8 mg per kg administered by a 60-minute intravenous infusion.

Administration of Intravenous formulation

* For patients with RA, GCA, COVID-19, CRS, PJIA, and SJIA patients at or above 30 kg, dilute to 100 mL in 0.9% or 0.45% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique.
* For PJIA, SJIA and CRS patients less than 30 kg, dilute to 50 mL in 0.9% or 0.45% Sodium Chloride Injection, USP for intravenous infusion using aseptic technique.
* Administer as a single intravenous drip infusion over 1 hour; do not administer as bolus or push.

Administration of Subcutaneous formulation

* Follow the Instructions for Use for prefilled syringe and prefilled ACTPen® autoinjector

Dose Modifications

* Recommended for management of certain dose-related laboratory changes including elevated liver enzymes, neutropenia, and thrombocytopenia.

drug label

Actemra prescribing information

Have more Actemra questions?

Submit MSL Request

Learn More

Need to report an Actemra issue?

ONLINE FORMReport adverse event

Learn More

samples

Request Actemra samples

NOT PROVIDED BY BRANDView Online Sample Form

Learn More

prior authorization

Actemra Prior authorization resources

Complete Letter of Medical Necessity

NOT PROVIDED BY BRANDCoverage Authorization Request

Coverage Authorization Appeals

Learn More

Benefits investigation

Rheumatology Subsequent Verification Program (RSVP) Enrollment Form

Actemra Prescriber Service Form

Actemra Prescriber Service Form - Online

Patient Consent Form

Patient Consent Form - Spanish

Learn More

Reimbursement help (FRM)

NOT PROVIDED BY BRANDReimbursement help (FRM) resources

Learn More

financial assistance

Actemra Financial assistance options

Co-pay savings program

commercial only

Actemra Prescriber Service Form

Actemra Prescriber Service Form - Online

Patient Consent Form

Patient Consent Form - Spanish

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Bridge program

commercial only

Actemra Prescriber Service Form

Actemra Prescriber Service Form - Online

Patient Consent Form

Patient Consent Form - Spanish

ACT Fast Bridge Program

Learn More

Overview

Provide patient immediate access to therapy during an insurance delay (typically new starts; some may cover change in insurance)
Limited time/ fill (typically 7-30 days; some may offer additional fill for continued delay up to certain limit)

Patient benefit

100% free (outside of insurance)

Patient eligibility

HCP must enroll patient
May be limited to commercially insured patients (i.e., no government beneficiaries); some programs may allow government beneficiaries

How to sign up

Typically HCP assisted enrollment (via form)

Foundation programs

under insured

no insurance

goverment insurance

65+

Patient Consent Form

Patient Consent Form - Spanish

Genentech Patient Assistance Foundation Prescriber Form

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement